Literature DB >> 20038979

Lung cancer: current diagnosis and treatment.

Stefan Hammerschmidt1, Hubert Wirtz.   

Abstract

BACKGROUND: Much progress has been made in the treatment of lung cancer in the last ten years (adjuvant chemotherapy, targeted therapy, individualized therapy). Nonetheless, lung cancer is still the leading cause of death due to cancer and thus remains a major medical, scientific, and social problem.
METHOD: This review is based on national and international recommendations and selected articles from the literature.
RESULTS: Cigarette smoking is the major pathogenic factor for lung cancer. Lung cancer can be divided into two major types that differ in their biological behavior, small cell lung cancer and non-small cell lung cancer. Whenever possible, the diagnosis should be confirmed by biopsy, the extent of disease should be documented in detail (international TNM classification/staging), and the patient's functional level should be assessed with a view toward treatment planning. Surgery for non-small cell lung cancer with curative intent is possible up to stage IIIA, while stage IIIB is the domain of radiotherapy. Surgery for small cell lung cancer with curative intent is possible for rare cases in early stages (T1N0 and T2N0, i.e., stage IA and IB). As long as small cell lung cancer is restricted to one side of the chest, simultaneous radiation therapy and chemotherapy are indicated. If a malignant pleural effusion or distant metastases are present, both lung cancers are treated palliatively with platinum-based chemotherapy.

Entities:  

Keywords:  cigarette smoking; diagnosis; lung cancer; targeted therapy; treatment

Mesh:

Year:  2009        PMID: 20038979      PMCID: PMC2797332          DOI: 10.3238/arztebl.2009.0809

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  31 in total

1.  [Recommendations on the diagnosis of bronchial carcinoma. German Pneumology Society].

Authors:  M Thomas; U Gatzemeier; R Goerg; W Matthiessen; H Morr; N Schönfeld; D Ukena; G Stamatis
Journal:  Pneumologie       Date:  2000-08

2.  Maintenance therapy in non-small-cell lung cancer.

Authors:  Thomas E Stinchcombe; Howard L West
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

3.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

4.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

Review 5.  Screening for lung cancer.

Authors:  R L Manser; L B Irving; C Stone; G Byrnes; M Abramson; D Campbell
Journal:  Cochrane Database Syst Rev       Date:  2004

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Authors:  Tudor Ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo Hang Kim; Maciej Krzakowski; Eckart Laack; Yi-Long Wu; Isabel Bover; Stephen Begbie; Valentina Tzekova; Branka Cucevic; Jose Rodrigues Pereira; Sung Hyun Yang; Jayaprakash Madhavan; Katherine P Sugarman; Patrick Peterson; William J John; Kurt Krejcy; Chandra P Belani
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 9.  Chemotherapeutic management of stage IV non-small cell lung cancer.

Authors:  Mark A Socinski; David E Morris; Gregory A Masters; Rogerio Lilenbaum
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 10.  Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Authors:  Michael K Gould; Ware G Kuschner; Chara E Rydzak; Courtney C Maclean; Anita N Demas; Hidenobu Shigemitsu; Jo Kay Chan; Douglas K Owens
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

View more
  27 in total

1.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

2.  Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features.

Authors:  Elham Tafsiri; Mojtaba Darbouy; Mohammad B Shadmehr; Anna Zagryazhskaya; Javad Alizadeh; Morteza Karimipoor
Journal:  Tumour Biol       Date:  2014-11-11

Review 3.  Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2021-01-03       Impact factor: 3.396

4.  Effect of magnetic fluid hyperthermia on lung cancer nodules in a murine model.

Authors:  Runlei Hu; Shenglin Ma; Hu Li; Xianfu Ke; Guoqing Wang; Dongshan Wei; Wei Wang
Journal:  Oncol Lett       Date:  2011-08-09       Impact factor: 2.967

5.  37-kDa laminin receptor precursor promotes lung adenocarcinoma cell invasion and metastasis by epithelial-to-mesenchymal transition.

Authors:  Y Wang; H Dong; M Xu; B Xin; W Niu; D Xu; P Zhao; B Zhang; Z Li; L Liu
Journal:  Cancer Gene Ther       Date:  2014-04-11       Impact factor: 5.987

Review 6.  The role of vimentin intermediate filaments in the progression of lung cancer.

Authors:  Martha E Kidd; Dale K Shumaker; Karen M Ridge
Journal:  Am J Respir Cell Mol Biol       Date:  2014-01       Impact factor: 6.914

Review 7.  The treatment of pleural carcinosis with malignant pleural effusion.

Authors:  Michael Ried; Hans-Stefan Hofmann
Journal:  Dtsch Arztebl Int       Date:  2013-05       Impact factor: 5.594

Review 8.  Microfluidic Exosome Analysis toward Liquid Biopsy for Cancer.

Authors:  Mei He; Yong Zeng
Journal:  J Lab Autom       Date:  2016-05-23

9.  The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.

Authors:  Shuang Li; Shuang Zhang; Jingjing Liu; Changliang Yang; Liang Zhang; Ying Cheng
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

10.  Methylation of RILP in lung cancer promotes tumor cell proliferation and invasion.

Authors:  Jianbo Lin; Yi Zhuo; Yinhe Yin; Linbin Qiu; Xu Li; Fancai Lai
Journal:  Mol Cell Biochem       Date:  2020-10-30       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.